Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner – A quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2

Abu-Id, 2006, Bisphosphonate-associated osteonecrosis of the jaw, Mund Kiefer Gesichtschir, 10, 73, 10.1007/s10006-005-0670-0 Aubin, 2002, Mesenchymal stem cell and osteoblast differentiation, 59 Balena, 1993, The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates, J Clin Invest, 92, 2577, 10.1172/JCI116872 Bamias, 2005, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors, J Clin Oncol, 23, 8580, 10.1200/JCO.2005.02.8670 Bedogni, 2006, Bisphosphonate-associated jawbone osteomyelitis: clinical, radiological and histological features, J Craniomaxillofac Surg, 34, 35, 10.1016/S1010-5182(06)60152-2 Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Bone, 2004, Ten years’ experience with alendronate for osteoporosis in postmenopausal women, N Engl J Med, 350, 1189, 10.1056/NEJMoa030897 Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, 1475, 10.1172/JCI119668 Cohen, 2006, The new bone biology: pathologic, molecular, and clinical correlates, Am J Med Genet A, 140, 2646, 10.1002/ajmg.a.31368 Coxon, 2006, Recent advances in understanding the mechanism of action of bisphosphonates, Curr Opin Pharmacol, 6, 307, 10.1016/j.coph.2006.03.005 Devogelaer, 1996, Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis, Bone, 18, 141, 10.1016/8756-3282(95)00436-X Dunford, 2006, Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases, J Bone Miner Res, 21, 684, 10.1359/jbmr.060118 Dunford, 2001, Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J Pharmacol Exp Ther, 296, 235 Fisher, 2000, In vivo effects of bisphosphonates on the osteoclast mevalonate pathway, Endocrinology, 141, 4793, 10.1210/en.141.12.4793 Fisher, 1999, Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, Proc Natl Acad Sci U S A, 96, 133, 10.1073/pnas.96.1.133 Fromigue, 2002, Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts, J Endocrinol Invest, 25, 539, 10.1007/BF03345497 Giuliani, 1998, Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo, Bone, 22, 455, 10.1016/S8756-3282(98)00033-7 Giuliani, 1998, Bisphosphonates stimulate the production of basic fibroblast growth factor and the formation of bone marrow precursors of osteoblasts. New findings about their mechanism of action, Minerva Med, 89, 249 Glatt, 2004, Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid, Osteoporos Int, 15, 707, 10.1007/s00198-004-1588-3 Guicheux, 2003, Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation, J Bone Miner Res, 18, 2060, 10.1359/jbmr.2003.18.11.2060 Hornby, 2003, Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats, Calcif Tissue Int, 72, 519, 10.1007/s00223-002-2015-4 Im, 2004, Osteoblast proliferation and maturation by bisphosphonates, Biomaterials, 25, 4105, 10.1016/j.biomaterials.2003.11.024 Lehenkari, 2002, Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite, Mol Pharmacol, 61, 1255, 10.1124/mol.61.5.1255 Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201 Luckman, 1998, Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure–activity relationships in J774 macrophages, J Bone Miner Res, 13, 1668, 10.1359/jbmr.1998.13.11.1668 Luckman, 1998, Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras, J Bone Miner Res, 13, 581, 10.1359/jbmr.1998.13.4.581 Luckman, 2005, JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras, J Bone Miner Res, 20, 1265, 10.1359/jbmr.2005.20.7.1265 Marx, 2005, Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment, J Oral Maxillofac Surg, 63, 1567, 10.1016/j.joms.2005.07.010 Mortensen, 1998, Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up, J Clin Endocrinol Metab, 83, 396, 10.1210/jc.83.2.396 Mundy, 1999, Stimulation of bone formation in vitro and in rodents by statins, Science, 286, 1946, 10.1126/science.286.5446.1946 Pataki, 1997, Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment, Anat Rec, 249, 458, 10.1002/(SICI)1097-0185(199712)249:4<458::AID-AR5>3.0.CO;2-N Pfaffl, 2001, A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Res, 29, e45, 10.1093/nar/29.9.e45 Ponader, 2008, In vitro response of hFOB cells to pamidronate modified sodium silicate coated cellulose scaffolds, Colloids Surf B Biointerfaces, 64, 275, 10.1016/j.colsurfb.2008.02.002 Roelofs, 2006, Molecular mechanisms of action of bisphosphonates: current status, Clin Cancer Res, 12, 6222s, 10.1158/1078-0432.CCR-06-0843 Rogers, 2000, Cellular and molecular mechanisms of action of bisphosphonates, Cancer, 88, 2961, 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004 Russell, 1999, Bisphosphonates: from the laboratory to the clinic and back again, Bone, 25, 97, 10.1016/S8756-3282(99)00116-7 Russell, 1999, The pharmacology of bisphosphonates and new insights into their mechanisms of action, J Bone Miner Res, 14, 53, 10.1002/jbmr.5650140212 Selander, 1996, Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages, Mol Pharmacol, 50, 1127 Storm, 1993, Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis, J Bone Miner Res, 8, 199, 10.1002/jbmr.5650080211 Tereshina, 2006, Ras-dva, a member of novel family of small GTPases, is required for the anterior ectoderm patterning in the Xenopus laevis embryo, Development, 133, 485, 10.1242/dev.02207 Tonino, 2000, Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group, J Clin Endocrinol Metab, 85, 3109, 10.1210/jc.85.9.3109 Tsuchimoto, 1994, Alendronate modulates osteogenesis of human osteoblastic cells in vitro, Jpn J Pharmacol, 66, 25, 10.1254/jjp.66.25 van Beek, 2003, Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates, Bone, 33, 805, 10.1016/j.bone.2003.07.007 Vandesompele, 2002, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, 3, 10.1186/gb-2002-3-7-research0034 von Knoch, 2005, Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells, Biomaterials, 26, 6941, 10.1016/j.biomaterials.2005.04.059 Walter, 2009, Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients, Cancer, 115, 1631, 10.1002/cncr.24119 Walter, 2008, Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate, Eur Urol, 54, 1066, 10.1016/j.eururo.2008.06.070 Walter, 2007, Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis, Support Care Cancer, 15, 197, 10.1007/s00520-006-0120-z Zhang, 1996, Protein prenylation: molecular mechanisms and functional consequences, Annu Rev Biochem, 65, 241, 10.1146/annurev.bi.65.070196.001325